Navigation Links
New Drugs May Offer Hope to Parkinson's Patients
Date:3/14/2013

By Kathleen Doheny
HealthDay Reporter

THURSDAY, March 14 (HealthDay News) -- Parkinson's disease has no cure, but three experimental treatments may help patients cope with unpleasant symptoms and related problems, according to new research.

The research findings will be presented at the annual meeting of the American Academy of Neurology in San Diego from March 16 to 23.

"Progress is being made to expand our use of medications, develop new medications and to treat symptoms that either we haven't been able to treat effectively or we didn't realize were problems for patients," said Dr. Robert Hauser, professor of neurology and director of the University of South Florida Parkinson's Disease and Movement Disorders Center in Tampa.

Parkinson's disease, a degenerative brain disorder, affects more than 1 million Americans. It destroys nerve cells in the brain that make dopamine, which helps control muscle movement. Patients experience shaking or tremors, slowness of movement, balance problems and a stiffness or rigidity in arms and legs.

In one study, Hauser evaluated the drug droxidopa, which is not yet approved for use in the United States, to help patients who experience a rapid fall in blood pressure when they stand up, which causes light-headedness and dizziness. About one-fifth of Parkinson's patients have this problem, which is due to a failure of the autonomic nervous system to release enough of the hormone norepinephrine when posture changes.

Hauser studied 225 people with this blood-pressure problem, assigning half to a placebo group and half to take droxidopa for 10 weeks. The drug changes into norepinephrine in the body.

Those on the medicine had a two-fold decline in dizziness and lightheadedness compared to the placebo group. They had fewer falls, too, although it was not a statistically significant decline.

In a second study, Hauser assessed 420 patients who experienced a daily "wearing off" of the Parkinson's medicine levodopa, during which their symptoms didn't respond to the drug. He compared those who took different doses of a new drug called tozadenant, which is not yet approved, with those who took a placebo. All still took the levodopa.

At the start of the study, the patients had an average of six hours of "off time" a day when symptoms reappeared. After 12 weeks, those on a 120-milligram or 180-milligram dose of tozadenant had about an hour less of "off time" each day than they had at the start of the study.

Tozadenant, which works on brain receptors thought to regulate motor function, merits further study in future trials, Hauser said.

In another study, Hauser looked at 321 patients with early stage Parkinson's whose symptoms weren't handled well by a medicine called a dopamine agonist, typically the first drug prescribed for Parkinson's patients. During the 18-week study, Hauser assigned them to take either their usual medicine plus an add-on drug called rasagiline (brand name Azilect) or their usual medicine and a placebo.

Azilect is approved for use in patients with early stage disease as a single therapy or as an add-on to levodopa, Hauser said, but not yet as an add-on to dopamine agonists.

Those taking the Azilect -- but not those taking the placebo -- improved by 2.4 points on a standard Parkinson's disease rating scale.

Costs of the still unapproved drugs are not known. Azilect costs about $200 monthly at the 1-milligram daily dose used in the study.

Each of the studies was funded by the pharmaceutical company making the particular drug: Chelsea Therapeutics paid for the blood-pressure study; Biotie Therapies Inc., supported the "wearing-off" study; and Teva Pharmaceutical Industries sponsored the Azilect study. Hauser is a consultant for all three companies.

Most impressive of the three studies is the use of droxidopa to prevent dizziness and fainting, said Dr. Michael Okun, national medical director of the National Parkinson Foundation and director of the University of Florida Center for Movement Disorders and Neurorestoration.

Drugs are already available to treat the problem, and compression stockings are also often recommended. Even so, "having another drug in that arena is going to help a lot of people," he said.

The effects of the other two treatments are more modest, said Okun, who is also a neurology professor. Additional studies will help determine how noteworthy the effects are in real life, he said.

Findings presented at medical meetings should be considered preliminary until published in a peer-reviewed medical journal.

More information

To learn more about Parkinson's disease, visit the National Parkinson Foundation.

SOURCES: Robert Hauser, M.D., professor of neurology and director, University of South Florida Byrd Parkinson's Disease and Movement Disorders Center, Tampa; Michael Okun, M.D., professor of neurology and director, University of Florida Center for Movement Disorders and Neurorestoration, and national medical director, National Parkinson Foundation, and author, "Parkinson's Treatment: 10 Secrets for a Happier Life"; American Academy of Neurology annual meeting, March 16 to 23, 2013, San Diego


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Pharmacy Robots Linked to Bacterial Contamination of Drugs
2. Penn study cautions use of drugs to block niacin flush
3. Urinary Incontinence Drugs May Be More Trouble Than Theyre Worth
4. Discovery could help to develop drugs for organ transplant and cancer patients
5. Not taking gastroprotective drugs prescribed with anti-inflammatory medicines
6. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
7. Weight-Loss Surgery Beat Drugs for Cutting Diabetes in Very Obese
8. Seniors Stop Taking Heart Drugs In Medicare Donut Hole
9. New Psoriasis Drugs Not Much Better Than Standard Therapy, Study Finds
10. About 1 baby born each hour addicted to opiate drugs in U.S., U-M study shows
11. Blood pressure drugs linked with lower PTSD symptoms
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New Drugs May Offer Hope to Parkinson's Patients
(Date:2/24/2017)... ... , ... With millions of Americans and people worldwide struggling ... are aware of our options and are empowered with strength and information throughout ... its newest edition of "Vision and Hearing" in USA Today, that will educate ...
(Date:2/24/2017)... ... , ... The narrative in “ Signal 8: An Australian Paramedic’s Story ” ... paramedic experiences. Schanssema describes the tragedies he saw, as well as his struggles with ... Schanssema, initially unsure of the career path he wanted to take, found fulfillment in ...
(Date:2/24/2017)... ... February 24, 2017 , ... The California State University ... academic faculty engaged in or interested in palliative care education and research. The Symposium, ... held in North County San Diego on Sept. 28 and 29, 2017, on the ...
(Date:2/24/2017)... ... ... The International Association of Eating Disorders Professionals (iaedp) announces the 2017 top five ... art competition. Selected from 15 submissions from around the nation, the top five finalists ... iaedp Symposium, March 22 – 26 in Las Vegas. , This year, the competition ...
(Date:2/24/2017)... ... 2017 , ... The Radiology Business Management Association will select the ... annual Building Better Radiology Marketing Programs conference, held this year from March ... Nine awards are given out in five categories. They are:, , ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Cogentix Medical, Inc. (NASDAQ: ... markets innovative proprietary products for the urology market, will ... year ended December 31, 2016 before the market open ... Company will host a conference call and webcast to ... March 9, 2017 at 11:00 a.m. Eastern Time (10:00 ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of the ... their offering. ... research Menopause Drugs Price Analysis and Strategies - 2016, provides drug pricing ... the following questions: What are the key ... in the Global Menopause market? What are the unit ...
(Date:2/23/2017)... DUBLIN , Feb. 23, 2017 Research ... Price Analysis and Strategies - 2016" report to their offering. ... The latest ... pricing data and benchmarks in the global Fibromyalgia market. ... are the key drugs marketed for Fibromyalgia and their clinical attributes? ...
Breaking Medicine Technology: